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William M. Abbott, MD, Boston, MassThank you Vice President Cantelmo for all those won-
derful memories. I’ve often wondered why the introduc-
tions of presidents of surgical societies are by tradition like
this, yet I’ve always enjoyed them. I especially enjoyed this
one, because it sounded so familiar. Many of you may not
have seen the president’s plaque (Fig 1) up close, with the
gavel made from Bob Linton’s oar and the names of now 31
presidents, with Linton at number 1 and me at number 30,
with lots of good people in between. I have looked at this
on the wall in front of my desk every day for the past year,
which brings me to express my sincere gratitude to all of
you who have honored me by electing me your president
this year. I was the youngest charter member of this society,
and ever since those beginnings, 30-plus years ago, I always
hoped I would become its president. Now that it has
happened, I can say I have treasured the experience. Thank
you so very much.
I remember our very first meeting, in Waterville Valley.
There were at best about 20 people present. One was the
volunteered slide projectionist, my first fellow, Randy Ma-
loney. There was no scientific program per se, only three
invited talks. One was by Roger Weisman on sympathec-
tomy, one by Nate Couch on embolism, and one by me on
noninvasive diagnosis, then a very new and yet-to-be ac-
cepted subject.
Bob Linton, our first president, missed the meeting,
because of failing health. And in fact he never made another
meeting. But I referred to his many contributions in my
introduction to the Robert R. Linton Distinguished Ad-
dress. And one is pivotal to my topic today, to which I will
return.
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The subject of this address is a vanishing commodity—
our time—and one way of alleviating or rescuing the situ-
ation. This won’t solve everything, but it can provide major
help. I do not really need to make a case that time is a
vanishing commodity for any practicing vascular surgeon in
this audience, or actually any surgeon anywhere. Compared
with 10 years ago, we are working increasingly hard, and for
more hours. In the last years it has gotten progressively
worse. And, of course, all the time we are continually being
paid less for what we do; we do more for less. Vascular
surgery has been hit particularly hard. In addition, we are
overwhelmed with paperwork, a flurry of different insur-
ance forms, the often complex referrals, the need to learn
ever-changing and more daunting computer skills, and
more. Our patients’ problems are becoming more challeng-
ing. At the same time, malpractice insurance premiums
continue to grow, practice expenses continue to increase,
and our own take-home earnings at least need to keep up
with inflation. And it just keeps getting worse. And still we
have to keep growing our practices just to make ends meet.
And it’s not just about money; it’s more about being able to
live a life. And so it is no great leap to conclude that
someone must do something about it.
Part of the problem is that our work is undervalued,
and we as physicians and surgeons are also undervalued by
society and government. We’ve lost the great respect we
had a few decades ago. Some of this is our own fault, and
some is not. This is a subject of some considerable com-
plexity, and I won’t discuss it further. But the system is out
of whack. We hope this will be rectified, sometime, but we
practitioners here today are without control over these
external events. So what are we to do? We need to look to
ourselves for solutions to the issue.
POSSIBLE PRESCRIPTION FOR RESCUE
So, what are our possible options for a prescription to
rescue vanishing time? Well, the first obvious one is to quit.
Many surgeons are doing that, either by retiring early or
seeking alternative careers. That sounds easy, but it isn’t.
We have been highly trained and motivated to do what we
do. We are dedicated to being vascular surgeons, and we1149
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us, for the field of vascular surgery, and for our patients. It
is not a viable answer.
The second option might be to cut back, reduce the
commitment to practice. Internists are forming “boutique”
practices, cutting their workload and charging extra for the
more personal services. That won’t and can’t work for
surgeons. So what cutting back means for us is work less,
earn less. Might work for some, and some will opt for it, but
not something that will work for most. Not a good option.
A third option is to demand or by some other means
achieve better reimbursement for what we do. My reaction
to that idea is, wonderful but unrealistic. I regret that it is
not at all a real option in today’s world.
The fourth option, which is the gist of my message
today, is to increase the clinical effectiveness of practice.
That, my colleagues, is my recommended prescription for
the rescue of time. This is something we can control, we can
dictate, we can direct, and we can achieve. And we can do so
Fig 1. President’s plaque, the Newrelatively quickly, and get and see results. I will describe
ways for doing this in a moment.
IMPORTANCE OF REGIONAL VASCULAR
SOCIETIES
To begin, I would like to say that, from our humble
beginning at Waterville Valley to today, the importance of
our regional vascular society continues to grow for us, the
members. Regional vascular societies are the grass roots of
the national organizations, which have become increasingly
unwieldy and decreasingly effective, especially as regards
situations like this. Perhaps that will improve with the new
organization: if bigger is better, yes; but the jury is still out.
Even so, they will increasingly need our help and support in
the future. But no matter how all that turns out, we here in
the New England Society for Vascular Surgery have much
more to say and do, and have a role to play in my prescrip-
tion for time rescue. In fact, in my opinion, it can only be
done locally, because we can help each other do it.
land Society for Vascular Surgery.Eng
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What do I mean by clinical effectiveness? Well, I will
describe it. There are three components, which are not
easily separable and are interdependent. But for descriptive
purposes I will consider each separately.
First is clinical outcomes improvement. Better results
will lessen inefficiency, which is a consumer of time for the
surgeon. The right operation for the right patient at the
right time avoids long-term adverse events down the road,
but also helps to streamline the “today” part. This piece is
highly dependent on evidence-based practice, to which I
will return in a moment, because it is so important.
Second is increased clinical efficiency, and that means
just what it says. It’s similar to but different from the time
saved by improved outcomes. It is also additive. Take less
time to do what needs to be done, which is tough to do
these days. Improved information technologies will even-
tually help, but they are slow in coming and very expensive
to implement. This very precious resource is being rationed
out over wide territories. Furthermore, we don’t really have
much control as to how much we can get and when. But the
other efficiency piece is clinical care-giving systems im-
provements, which is something we can control and do
ourselves. And I’ll come back to it in considerable detail.
But to repeat, it is deeply embedded in the whole of clinical
effectiveness.
Third is bad result or morbidity reduction. This is
obvious. You, of course, can see how interrelated these are,
but what you will see in a minute is how the methods differ
to approach and rectify related problems.
LIFE TABLE METHOD
As I mentioned earlier, Bob Linton made many contri-
butions over his career (Table I). The one contribution I
want to come back to is the introduction of the life table
method of reporting results. He and Clem Darling were the
first to use this in their description of the results of saphe-
nous vein grafting1 (Fig 2). A novelty at the time, a stan-
Fig 2. Reproduction of the classic 1967 paper first usi
sults.dard now. This led the way to better ways of reporting and
predicting results. You all know this method, so I won’t
describe it further. But the beauty of it was that it was a
retrospective analysis used in a way to turn things around to
get reliable and credible predictive outcomes, and earlier
than they occurred. They adapted the actuarial methods
used by insurance companies to predict how long clients
would live, for example, so as to know how much premiums
should be so as not to lose money. But Linton and Darling
were the first to use this method for reporting vascular
surgery results. There are, of course, more sophisticated
ways of doing this now, and also better methods to obtain
results. But the basic premise was, and still is, valid. We
need to know with as much precision as possible what the
outcomes are of what we do. This is not a new mantra;
Norman Hertzer expressed it well in the title of his 1994
Society for Vascular Surgery Presidential Address: “Out-
come assessment in vascular surgery: results mean every-
thing.”2 But that was 1994, and still we haven’t progressed
very far. We need to move toward greater use of evidence-
based information.
EVIDENCE-BASED SURGERY
Clinical effectiveness is evidence-based; it is one of the
cornerstones of the process. Of course, if we don’t have
outcomes information, then we don’t know the evidence.
Sounds like a circle, but it isn’t. Properly conducted out-
comes studies lead to evidence-based practice. It’s linear.
And we aren’t good enough at this yet. Vascular surgery, to
its credit, has brought this concept farther than most sur-
gical fields. But we are still far behind where we need to be.
Consider this year’s annual meeting. As you know,
there are rules of clinical evidence, developed by Sackett.3
They have subsequently been modified and are somewhat
more complicated, but are clearly explained in a recent
paper by Clagget.4 But the original concept is straightfor-
ward. Level I is the best, with high confidence that the
evidence is credible and reliable. And it goes down hill from
e Life Table Method for reporting vascular surgery re-ng th
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ing. I excluded four basic research papers, four case reports,
and three coming from administrative databases, which are
retrospective by definition, but do have some credibility by
virtue of sheer number. Based on the abstracts, I could not
decide how to judge them. Of the remainder, and I am
being generous, 77% were at best level III studies. There
were maybe three level II studies in the remainder, and no
level I studies.
So we all meet for a couple of days, listening to data,
much of which is of uncertain value by definition of the
rules of evidence-based practice. I know this sounds harsh,
and, please, authors at our meeting, don’t take too much
umbrage with me. But clearly we need to do better than
this.
CPM: THE THERAPEUTIC ARM
So let’s start with my prescription for time rescue. To
do this, I will tell you the story of how a clinical effectiveness
program developed at one institution, my own, the Massa-
chusetts General Hospital (MGH), and how that led to my
conclusion that this approach could result in rescue of some
of our vanishing time.
In 2000 the MGH administration launched a program
they entitled Clinical Performance Management, or CPM.
It doesn’t make any difference what it’s called, but what it
does is important. But for this task I will continue to refer to
it as CPM. Although veiled in noble intentions, its original
primary target was clearly on length of stay reduction and
hospital capacity management. Although these are clearly
important, they are also clearly economic. Not much help
here for us. But here is what happened.
The program was launched with four goals:
1. Improve the quality of patient care.
2. Increase the efficiency of our care delivery process.
3. Optimize the use of our impatient and outpatient capac-
ity.
4. Improve the quality of professionals’ practice lives.
Vascular Surgery, along with General Surgery and Tho-
racic Surgery, were instructed to put together programs to
achieve these objectives. From the outset, we chose to work
as an integrated group, focusing on global issues germane
and generic to surgery while relegating service- specific




● Linton tube (esophageal varices)
● Splenorenal venous shunt (portal hypertension)
● Saphenous vein femoropopliteal reconstruction
● Life table reporting method
● Linton flap (post-phlebitic syndrome)
● Founding member of the Society for Vascular Surgery, and
ninth president
● Founding member of the New England Society for Vascular
Surgery, and first presidentissues to those individual services. We invited participation
from everyone involved in the patient care process: sur-
geons, residents, nurse managers, nurses, nurse practi-
tioners, case managers, physical therapists, administra-
tors—everybody. And it worked. And it is still working.
But it has evolved in a positive way for some very specific
reasons, which I will elaborate on in a moment. In the first
year we focused on goals 2 and 3, sort of because we were
directed there. Those were increased efficiency of care
delivery and optimized use of hospital capacity.
In the first year we accomplished the desired results: a
length of stay reduction of 10% to 20%; an increase in the
number of discharges before noon to 30% to 40%, thereby
improving capacity; and a reduction in the number of
“avoidable” hospital days attributable to physician “prefer-
ence” by 20%, among other things. No mean accomplish-
ment. But the important thing is that during this time the
group grew increasingly cohesive, collegial, and imagina-
tive.
In the second year we shifted our focus to goals 1 and 4,
that is, improve the quality of patient care and the quality of
professionals’ practice lives.
Here is where it got interesting, because we were now
substantially involved with quality issues in patient care, as
well as efficiency. Time does not permit a lengthy exposi-
tion of the CPM program here, and an explicit description
of the program will be published in detail subsequently. But
the key to success has been enhanced communication be-
tween the multidisciplinary members of the care team,
because we had to work together as a team. Traditional
vertical “silo” sorts of relationships became horizontal and
interactive. Nursing responsibilities were sharpened and
advanced by development of protocols for nurses’ initial
management of common problems such as atrial fibrilla-
tion, nausea, and hypokalemia. Scut work for residents and
staff was reduced. But problems were solved, and much
change was effected. These include better information
about the inpatient experience provided; protocols to en-
hance the efficiency of the discharge process; methods to
decrease the number of pages to residents, resulting in a
26% reduction; smoothing of the operating room schedule
to even out late work days; and even the establishment of
protocols for managing alcohol withdrawal to reduce mor-
bidity, to cite just a few. But everybody benefitted. And
when added up, the quality of care improved, as did the
quality of professional lives. Yet the latter was, unfortu-
nately, somewhat difficult to appreciate, especially for the
surgeons. It was not enough to claim success, even though
we could illustrate improvement by adding the small pieces.
But there were no sweeping changes or major targeted
initiatives for the benefit of professional lives. Success in-
stead was achieved by many small steps along the way, all
adding up to build impact. But the longer we worked
together the more innovative the program became. The
steps became bigger and the initiatives bolder, and things
continued to improve.
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systems and the effector of change. I call it the therapeutic
arm of clinical effectiveness. But still this was not enough.
CPM: THE DIAGNOSTIC ARM
We reasoned that if there is a therapeutic arm, then
there ought to be a diagnostic arm as well. And we found
one. Although quality improvements for patients were
beginning to occur, the quality of professional lives, and
especially staff surgeons’ lives, was harder to see. We lacked
the kind of systematic data needed to make a bigger effect
that we could specifically measure. We had a therapeutic
arm, but we needed that diagnostic arm to, so to speak,
move forward.
And then we got lucky. Shukri Khuri, the principal
investigator of the Veterans Affairs (VA) National Surgical
Quality Improvement Program (NSQIP), invited us to
become one of 14 study centers to test the hypothesis that
the methods that had worked dramatically for the VA could
also be applied to and work in the private, non-government
sector. We accepted, and I became principal investigator for
our site.
Most of you, I assume, know about NSQIP.5,6 But in
brief review, it was the VA response to a government
mandate to improve the quality of surgical outcomes in the
VA. This ensued because of much negative publicity about
poor surgical results in the 1980s. What they did was build
a program across all the VA hospitals in which data about all
surgical procedures were randomly, but prospectively,
Fig 3. Effect of risk adjustment for 30-day mortality ra
hospitals are realigned.gathered and entered by protocol into a centralized data-
base. Major end points, mortality and morbidity, were
recorded at 30 days post-operative. The data were risk-
adjusted by analyzing a number of preoperative, possibly
risk-additive variables. Then, using statistical methods, they
determined a predicted outcome or expected event rate.
Obviously, based on the collected data, they then could
calculate an observed or expected event rate, an O/E ratio,
for each site, depending on outcomes. An O/E ratio of 1
should be the norm. A low outlier, that is, an O/E ratio
statistically less than 1, is good; a high outlier, that is, an
O/E statistically higher than 1, is not good. Then they
ranked the hospitals from lowest to highest, again with the
lowest O/E being the best, as illustrated in their first
publication.5 All of this was validated statistically as they
went along. But the essential ingredient was risk adjust-
ment. If the hospitals were ranked without risk adjustment,
the order was entirely different from that after risk adjust-
ment, with some of the low-ranking hospitals going to the
highest ranking, and vice versa, as shown in Fig 3, where 1
is best. They found that unadjusted outcomes have a 60%
error rate in identifying outliers.
After O/E ratios were established for all 128 VA hos-
pitals, site visits were made to the high outliers and the low
outliers. The information gathered at low outliers was
implemented at high outliers. During the site visits they
found that the differences were not really in the caregivers’
skills, but mainly in the systems of care. The results were
astounding, as shown in Table II, with these methods and
, where high-ranking and low-ranking Veterans Affairsnking
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27%, and morbidity by 45%. Postoperative length of stay
declined from 9 days to 4 days in the presence of no change
in risk profile or volume and complexity of operations.
Patient satisfaction improved. Within 2 years high outliers
had dropped to average or below.6
So it was an extremely logical step to try this in non-VA
hospitals, first, to see if it could be done, and second, to see
whether it could achieve a similar effect. I can report now
that the trial is more than 18 months along, and is working.
In 14 private sector hospitals (Table III) only general and
vascular surgical cases are collected by dedicated and spe-
cifically trained nurse reviewers. Otherwise, everything else
is the same: prospective, objective, risk-adjusted informa-
tion at 30 days. As of September 1, 2003, in the private
sector study there were 45,327 patients entered; 7312 of
these were vascular surgery patients. Thirty-day follow-up
was complete for 96% of patients. Thus the first question is
answered: data can be collected accurately in the private
sector.
At the most recent analysis of the private sector centers
data we saw both low and high outliers emerging in both
mortality and morbidity in both general and vascular sur-
gery cases. Fig 4 demonstrates the various morbidity rates
for only vascular surgery. However, the confidence intervals
are still broad at most sites, because of insufficient case
numbers to have it anywhere near sorted out. But the
intervals are getting narrower, and already there are outliers
shown, where site 2, for example, is a low outlier and site 13
is clearly a high outlier. Work is ongoing to develop the
Table II. VA NSQIP results: 1991-2001
● 27% reduction! In postoperative mortality
● 45% reduction! In postoperative morbidity
● Median postoperative length of stay declined from 9 days to 4
days
● Volume and complexity of major operations unchanged
● Risk profiles of patients unchanged
● Patient satisfaction improved
● All high outliers at or below average after 2 years
VA NSQIP, Veterans Affairs National Surgical Quality Improvement Pro-
gram.
Table III. Beta test sites for private sector study
● Emory University
● University of Kentucky
● University of Michigan
● Barnes-Jewish Hospital
● Brigham & Women’s Hospital
● University of Florida, Shands Hospital
● University of California, San Francisco
● University of Maryland, Baltimore
● University of Utah
● University of Virginia
● New York Presbyterian, Columbia University
● New York Presbyterian, Cornell University
● Massachusetts General Hospital
● St Louis Universitytools for corrective interventions in a systematic way. We
also are provided detailed reports on incidence and types of
morbidities recorded. At the MGH, for example, we have a
higher than anticipated urinary tract infection (UTI) rate.
We don’t need to define a UTI; that’s done by the system.
We don’t need to validate the data collection, because our
nurse reviewers’ accuracy has already been verified by a
national coordinator at a recent site visit, and they passed
with flying colors. What we are going to do is go back and
study the effect of these UTIs in both a clinical and eco-
nomic sense.
But in so doing, we are connecting the diagnostic arm
to the therapeutic arm, using CPM methods already in
place, which will determine why these infections occur and,
it is hoped, identify ways to reduce their incidence. And,
voila!—a real clinical effectiveness study.
We had already analyzed the first 164 vascular surgery
cases for economic effect of morbidity. Remember that this
is a random sample of a bigger total number performed.
But because of the data collection scheme, it should be
reasonably reliable, especially in view of the rather dramatic
findings shown in Table IV. In those cases without compli-
cations, compared with those cases with complications, the
length of stay increases from 5.3 days to 16.9 days, the
hospital costs rise from $17,200 to $46,400, and the
hospital reimbursement margin goes from positive to neg-
ative. No small effect.
But back to UTIs. Now, I would certainly concede that
reducing the UTI rate won’t be a great rescue of our time.
But it is a beginning, a method, a route to get to time savers
and rescue by both cumulative small steps plus some bigger
ones as the numbers grow, and we can ferret out some more
major morbidities. At the same time, we will learn efficien-
cies we haven’t thought of yet, which will lead to improved
clinical effectiveness even without accompanying morbidity
reductions. And through such clinical effectiveness we will
rescue our time. Like George Foreman says in the muffler
ad, “I guarantee it.”
Think of the ways this will save time. Less time at sick
patients’ bedsides, less time with multiple worried family
members, less time with documentation, less time with
hassling with insurance carriers, and the list goes on.
Of course, this isn’t the only reason to do this. It is
good for patient care, and the public is increasingly de-
manding evidence of outcomes and results. Insurance car-
riers and the government are surely going to tie it to
reimbursement. But I stress, and this is the point of my
message this morning, that it is also beneficial to us. Per-
haps this is secondary to the others, but not too secondary,
because if we don’t do something to rescue ourselves and
our time the machinery is going to break down, and every-
one loses.
I am sure that there are some skeptics among you who
are muttering, “Well, that’s OK for the MGH, with all their
money and resources.” Well, I would respond to you that,
yes, you need some money and some resources. But the
return on investment is huge, as illustrated by the economic
effect. And it does not need to be done in perhaps such a
JOURNAL OF VASCULAR SURGERY
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academic project or program, and have recently established
a Center for Clinical Effectiveness in Surgery at the MGH
as an educational and clinical research vehicle, as well as to
do what I have described.
But I stress, you don’t need an elaborate program to
achieve what I recommend. A therapeutic CPM-type pro-
gram is easy to set up, and once established it doesn’t cost
much of a surgeon’s time. NSQIP methods are adaptable at
community hospitals, and probably will soon become
widely available nationally. The American College of Sur-
geons has become involved to turn this into a truly national
program. In Massachusetts, Newton Wellesley Hospital,
Fig 4. Observed-expected ratio for vascular surgery mor
(eg, sites 1 and 2) and high outliers (eg, sites 6, 13, and
Table IV. Effect of morbidity on length of stay, costs, and




LOS, Length of stay.Faulkner Hospital, and North Shore Medical Center have
all joined NSQIP, not as study centers such as we are, but as
users of the system for which it was originally intended. But
I have learned over the time since we started the Center, it
is the simple and logical tools that are not only adequate but
work the best. And if you start simply, things will build and
success will be achieved. So if you buy my theory that
clinical effectiveness is a prescription for rescue of time,
then the case is closed.
CONCLUSION
I hope you agree with my hypothesis that increased
clinical effectiveness will serve to rescue your vanishing
results for 14 private sector hospitals noting low outliers
bursement margin: Early results in 164 patients
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on it—a prescription, if you will.
1. Go home and plan a clinical effectiveness project. There
is a simple formula promulgated by management types,
but it works. It’s called PDSA,7 and, incidentally, the
Joint Commission loves it: plan a project, do it, study the
results, and act on the results.
I would add a fifth letter, R: restudy the results for effect.
One effect should be the rescue of your time, your
personal payoff. But you will also find that if you involve
everybody, all caregivers including physicians, nurses,
case managers, administrators—everyone key to process
or systems in your hospital—communications will be
advanced. Everything, including morale, will start to
improve. But this is the therapeutic arm, no matter how
you wish to construct it. It must come first.
2. Develop a diagnostic arm. By a diagnostic arm, of course
I mean some sort of prospective outcomes project to
broaden the status and quality of data. It enhances the
perspective. This can be done simultaneously with de-
velopment of the therapeutic arm, but that makes for a
much greater commitment. I would recommend that in
most places they be staged. But diagnosis must follow
therapy; a therapeutic arm can stand by itself, the diag-
nostic arm cannot. Who cares if we know what’s wrong
if there is no way to remedy it.
This diagnostic arm can involve many of the same
people already in place for the first step, but new players
will need to be added. This is the group that will focus
on the PDSA-R formula.
One should start with simple projects, such as the ap-
propriate use of perioperative antibiotic agents, or deep
venous thrombosis prophylaxis, or perioperative beta
blockade. Then move on to something more complex,
such as wound infection or graft failure. As you move
along, solicit “buy-in” from nonparticipants and skep-
tics. I suspect you will not find this too difficult as
momentum and enthusiasm grow.
3. Connect the diagnostic arm to the therapeutic arm. This
is not so straightforward as it sounds, and requires theutmost cooperation and support. But we’ve shown that
it can be done.
4. Once the therapeutic arm has outlined solutions to the
problems identified by the diagnostic arm, execute
them. This is the hardest step of all, because it means
change, maybe a lot of change. But if you have suc-
ceeded with steps 1, 2, and 3, then it should happen.
The enhanced communications will help. Remember
this concept: it will work if you make it easy for people to
do the right thing.
5. But remember, our patients, our most important re-
sponsibility, will benefit from these efforts. So will your
institution. And, very important, so will you, with a
resulting rescue of your time.
The future is in our hands. Carpe diem!
I express great appreciation to Jamie Brown, who suf-
fered through the many drafts of this address, and the many
members of the Clinical Performance Management and
Center for Clinical Effectiveness in Surgery teams, who all
contributed in many ways to the ideas espoused herein.
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